Applying Novel Study Designs to Study Treatment Discontinuation: Contrasting Cloning, Censoring, and Weighting to a Prevalent New User Approach

Applying Novel Study Designs to Study Treatment Discontinuation: Contrasting Cloning, Censoring, and Weighting to a Prevalent New User Approach

Summary

About the presentation: Estimating the effects of discontinuation, deprescribing, or otherwise stopping drug treatments using observational data has been and continues to be extremely challenging. Two newer study designs (cloning, censoring, and weighting and a prevalent new user approach) have the potential to avoid immortal time and other self-inflicted biases common in studies of discontinuation. That said, what exactly each design estimates differ in subtle but important ways. This presentation will go over these distinctions and discuss important strengths and weaknesses of these designs for drug discontinuation studies.

About the presenter:  Michael Webster-Clark is a pharmacoepidemiologist who specializes in epidemiologic methods research, with a focus on novel study designs and extending inferences to external target populations.